Health Condition 1: R978- Other abnormal tumor markers
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Aster CMI Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Stage III and IV high grade serous and endometrioid ovarian, fallopian or primary peritoneal cancer confirmed histologically Planned for neoadjuvant chemotherapy with Paclitaxel and Carboplatin with or without Bevacizumab
Exclusion criteria
Exclusion criteria: Patients undergoing primary cytoreductive surgery Known germline BRCA mutation Inadequate pre-treatment biopsy tissue for HRD testing Complete response at the time of interval cytoreductive surgery Prior chemotherapy immunotherapy or targeted therapy at diagnosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome Measure Concordance of HRD status between pretreatment biopsy specimen and post neoadjuvant chemotherapy surgical specimen Timepoint: Baseline before neoadjuvant chemotherapy and after completion of neoadjuvant chemotherapy at interval cytoreductive surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome Measure Progression free survival in patients with stable HRD status compared with patients showing HRD conversion following neoadjuvant chemotherapyTimepoint: Twenty four months from diagnosis or until first recurrence whichever occurs earlier You can directly copy and paste this into the CTRI outcome section. | — |
Countries
India
Contacts
Public ContactDrMythili Kundur
Aster CMI Hospital
Outcome results
None listed